ARTICLE | Company News
Actelion sales and marketing update
July 29, 2013 7:00 AM UTC
Actelion disclosed in its 1H13 earnings that at the end of 2Q13 it launched 0.5 and 1.5 mg epoprostenol as Epoprostenol ACT in Japan to treat pulmonary arterial hypertension (PAH). The formulation of...